These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 36226398

  • 21. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
    Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, Smaletz O, Schutz F, Herchenhorn D, Santos T, Mavignier Carcano F, Queiroz Muniz D, Nunes Filho PRS, Zaffaroni F, Barrios C, Fay A.
    BMC Cancer; 2019 May 23; 19(1):487. PubMed ID: 31122212
    [Abstract] [Full Text] [Related]

  • 22. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
    Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Mori K, Sano T, Otsuka T, Iwamoto Y, Enei Y, Nakazono M, Sakanaka K, Iwatani K, Matsukawa A, Atsuta M, Nishikawa H, Tsuzuki S, Miki J, Habuchi T, Ohyama C, Shariat SF, Egawa S.
    World J Urol; 2023 Aug 23; 41(8):2051-2062. PubMed ID: 35596809
    [Abstract] [Full Text] [Related]

  • 23. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
    Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Juárez Soto Á, Uemura H, Ye D, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN.
    Ann Oncol; 2023 May 23; 34(5):477-485. PubMed ID: 36858151
    [Abstract] [Full Text] [Related]

  • 24. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
    Zhang X, Zhang G, Wang J, Bi J.
    Front Endocrinol (Lausanne); 2023 May 23; 14():1131033. PubMed ID: 36843606
    [Abstract] [Full Text] [Related]

  • 25. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb 23; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 26. Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
    Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Soto ÁJ, Uemura H, Ye DW, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN.
    Future Oncol; 2024 Mar 23; 20(10):563-578. PubMed ID: 38126311
    [Abstract] [Full Text] [Related]

  • 27. Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide.
    Fujmoto S, Fujita K, Nishimoto M, Hamaguchi M, Kuwahara K, Hashimoto M, Adomi S, Minami T, Nozawa M, Yoshimura K, Uemura H.
    Cancer Med; 2023 Feb 23; 12(3):3176-3179. PubMed ID: 36043427
    [Abstract] [Full Text] [Related]

  • 28. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 23; 37(1):512-526. PubMed ID: 31813087
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
    Li JR, Wang SS, Chen CS, Yang CK, Lu K, Cheng CL, Hung SC, Chen SY, Hsu CY, Chiu KY.
    Anticancer Res; 2022 Oct 23; 42(10):4857-4866. PubMed ID: 36191989
    [Abstract] [Full Text] [Related]

  • 30. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N, Jiang S, Garcia-Horton V, Terasawa E, Steffen D, Chin A, Ayyagari R, Partridge J, Waldeck AR.
    Adv Ther; 2022 Nov 23; 39(11):5025-5042. PubMed ID: 36028656
    [Abstract] [Full Text] [Related]

  • 31. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.
    Saad F, Bögemann M, Suzuki K, Shore N.
    Prostate Cancer Prostatic Dis; 2021 Jun 23; 24(2):323-334. PubMed ID: 33558665
    [Abstract] [Full Text] [Related]

  • 32. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
    Wallis CJD, Chandrasekar T, Goldberg H, Klotz L, Fleshner N, Satkunasivam R, Klaassen Z.
    Eur Urol Oncol; 2018 Aug 23; 1(3):238-241. PubMed ID: 31102627
    [Abstract] [Full Text] [Related]

  • 33. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF.
    Int J Clin Oncol; 2020 Nov 23; 25(11):1892-1900. PubMed ID: 32924096
    [Abstract] [Full Text] [Related]

  • 34. Hormonal Therapy for Prostate Cancer.
    Desai K, McManus JM, Sharifi N.
    Endocr Rev; 2021 May 25; 42(3):354-373. PubMed ID: 33480983
    [Abstract] [Full Text] [Related]

  • 35. Managing Nonmetastatic Castration-resistant Prostate Cancer.
    Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS.
    Eur Urol; 2019 Feb 25; 75(2):285-293. PubMed ID: 30119985
    [Abstract] [Full Text] [Related]

  • 36. Using darolutamide in advanced prostate cancer: How I Do It.
    Hamilton J.
    Can J Urol; 2021 Jun 25; 28(3):10673-10677. PubMed ID: 34129460
    [Abstract] [Full Text] [Related]

  • 37. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S, TITAN Investigators.
    N Engl J Med; 2019 Jul 04; 381(1):13-24. PubMed ID: 31150574
    [Abstract] [Full Text] [Related]

  • 38. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
    Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, Small EJ.
    JAMA Oncol; 2021 Jul 01; 7(7):1005-1014. PubMed ID: 34081076
    [Abstract] [Full Text] [Related]

  • 39. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
    Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, Feng FY, Rajpurohit Y, Urtishak K, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu M, Wyatt AW, Li M, Attard G, Small EJ.
    Clin Cancer Res; 2021 Aug 15; 27(16):4539-4548. PubMed ID: 34112710
    [Abstract] [Full Text] [Related]

  • 40. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532).
    Tombal BF, Gomez-Veiga F, Gomez-Ferrer A, López-Campos F, Ost P, Roumeguere TA, Herrera-Imbroda B, D'Hondt LA, Quivrin M, Gontero P, Villà S, Khaled H, Fournier B, Musoro J, Krzystyniak J, Pretzenbacher Y, Loriot Y.
    Eur Urol Oncol; 2024 Oct 15; 7(5):1051-1060. PubMed ID: 38272747
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.